Cambridge, MA, USA and Berlin, Germany, December 5, 2016 – InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi). As part of the GALS program, InGeneron has established an additional US presence in Cambridge, MA.

“Our new presence in Cambridge will help us access one of the world’s leading life sciences and biotechnology hubs and tap into the local talent pool,” said Michael Coleman, Ph.D., Chief Executive Officer of InGeneron. “Additionally, being accepted into the GALS program is a commendation for our teams on both sides of the Atlantic. The broad network and expertise of GALS represents a significant opportunity for the company.”

“We are excited to start our collaboration with InGeneron. The company’s adipose-derived regenerative cell-based technology has great potential across several indications. We are confident that GALS can add significant value and help InGeneron establish its innovative approach in the US and Europe,” commented Christoph Lengauer, Ph.D., MBA, CEO of the German Accelerator Life Sciences.

GALS will provide InGeneron with a team of mentors and leverage its industry network to support the company’s US activities and development in Europe. GALS’ mentorship will support InGeneron as the company continues to execute on its plans for clinical development in the US, expanding its distribution network, further developing its reimbursement strategies in the US and Europe, and broadening its investor base.

About the Transpose® RT System and FDA approved clinical trials
InGeneron’s Transpose® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase®, a proprietary enzyme mixture. The platform allows the isolation of regenerative cells from the patients’ own adipose tissue at point-of-care in less than 90 minutes for same-day treatment. The cells are re-administered into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance.
The Transpose® RT System is being investigated in several FDA-approved clinical trials and is currently available in the U.S. for research use only. More information on InGeneron’s actively enrolling clinical trials can be found at under the identifiers NCT03752827NCT03513731, and NCT03503305.

About InGeneron
InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA.


InGeneron, Inc.
Eckhard Alt, MD, PhD
Executive Chairman of InGeneron
+1 (713) 440 9900
[email protected]

Media Inquiries
Jon Stone
Stone Communications Consulting
+1 (612) 475 5955
[email protected]